{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:13:12Z","timestamp":1772777592789,"version":"3.50.1"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>The combination of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor elbasvir and the NS3\/4A protease inhibitor grazoprevir is a potent, once-daily therapy indicated for the treatment of chronic HCV infection in individuals coinfected with human immunodeficiency virus (HIV). We explored the pharmacokinetic interactions of elbasvir and grazoprevir with ritonavir and ritonavir-boosted HIV protease inhibitors in three phase 1 trials.<\/jats:p>","DOI":"10.1128\/aac.02142-18","type":"journal-article","created":{"date-parts":[[2019,2,11]],"date-time":"2019-02-11T11:56:18Z","timestamp":1549886178000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers"],"prefix":"10.1128","volume":"63","author":[{"given":"Hwa-Ping","family":"Feng","sequence":"first","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2275-8771","authenticated-orcid":false,"given":"Luzelena","family":"Caro","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Fandozzi","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Chu","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zifang","family":"Guo","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Talaty","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Panebianco","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Dunnington","sequence":"additional","affiliation":[{"name":"Celerion, Inc., Lincoln, Nebraska, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Du","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Hanley","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain P.","family":"Fraser","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mitselos","sequence":"additional","affiliation":[{"name":"MSD Europe, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Francois","family":"Denef","sequence":"additional","affiliation":[{"name":"MSD Europe, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"De Lepeleire","sequence":"additional","affiliation":[{"name":"MSD Europe, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan N.","family":"de Hoon","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium"},{"name":"Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Vandermeulen","sequence":"additional","affiliation":[{"name":"Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William L.","family":"Marshall","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Jumes","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobi","family":"Huang","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Martinho","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Valesky","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan R.","family":"Butterton","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy W.","family":"Yeh","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Global hepatitis report, 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. 2017. Global hepatitis report, 2017. World Health Organization, Geneva, Switzerland. https:\/\/afro.who.int\/sites\/default\/files\/2017-06\/9789241565455-eng.pdf."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007348"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/321909"},{"key":"e_1_3_3_5_2","volume-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","author":"Department of Health and Human Services","year":"2016","unstructured":"Department of Health and Human Services. 2016. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, updated 30 May 2018. Department of Health and Human Services, Washington, DC. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis367"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201300343"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00324-12"},{"key":"e_1_3_3_9_2","volume-title":"Zepatier. Annex I. Summary of product characteristics","author":"Merck Sharp & Dohme","year":"2018","unstructured":"Merck Sharp & Dohme. 2018. Zepatier. Annex I. Summary of product characteristics. Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire, UK. http:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20171130139565\/anx_139565_en.pdf."},{"key":"e_1_3_3_10_2","volume-title":"Zepatier [prescribing information]","author":"Merck & Co","year":"2018","unstructured":"Merck & Co. 2018. Zepatier [prescribing information]. Merck & Co., Inc., Kenilworth, NJ. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0816"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.09.045"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00349-9"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0785"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00114-9"},{"key":"e_1_3_3_16_2","first-page":"437A","article-title":"Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and midazolam, pitavastatin, and atorvastatin in healthy volunteers","volume":"58","author":"Caro L","year":"2013","unstructured":"Caro L, Talaty JE, Guo Z, Reitmann C, Fraser IP, Evers R, Swearingen D, Yeh WW, Butterton JR. 2013. Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and midazolam, pitavastatin, and atorvastatin in healthy volunteers, abstr 477. Hepatology 58(Suppl 1):437A. https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/hep.26727.","journal-title":"Hepatology"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498250903509375"},{"key":"e_1_3_3_18_2","volume-title":"Kaletra (lopinavir and ritonavir) tablet for oral use and Kaletra (lopinavir and ritonavir) oral solution [prescribing information]","author":"AbbVie","year":"2017","unstructured":"AbbVie. 2017. Kaletra (lopinavir and ritonavir) tablet for oral use and Kaletra (lopinavir and ritonavir) oral solution [prescribing information]. AbbVie, Inc., North Chicago, IL. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021251s052_021906s046lbl.pdf."},{"key":"e_1_3_3_19_2","first-page":"442a","article-title":"Pharmacokinetic interactions between the HCV protease inhibitor MK-5172 and ritonavir-boosted HIV protease inhibitors (atazanavir, lopinavir, darunavir) in healthy volunteers","volume":"58","author":"Caro L","year":"2013","unstructured":"Caro L, Talaty JE, Guo Z, Fraser IP, Davis HU, O\u2019Reilly T, Yeh WW, Butterton JR. 2013. Pharmacokinetic interactions between the HCV protease inhibitor MK-5172 and ritonavir-boosted HIV protease inhibitors (atazanavir, lopinavir, darunavir) in healthy volunteers, abstr 487. Hepatology 58(Suppl 1):442a. https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/hep.26727.","journal-title":"Hepatology"},{"key":"e_1_3_3_20_2","first-page":"315","article-title":"Ritonavir-boosted atazanavir, lopinavir, and darunavir increase HCV NS5A inhibitor MK-8742 levels","volume":"22","author":"Yeh WY","year":"2014","unstructured":"Yeh WY, Marshall W, Ma J, Mangin E, Huang X, Jumes P, Youngberg S, Butterton J. 2014. Ritonavir-boosted atazanavir, lopinavir, and darunavir increase HCV NS5A inhibitor MK-8742 levels, abstr 638. Top Antiviral Med 22:315. https:\/\/www.iasusa.org\/wp-content\/uploads\/2014\/04\/apr_2014.pdf.","journal-title":"Top Antiviral Med"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61795-5"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28877"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.050"},{"key":"e_1_3_3_24_2","first-page":"324","article-title":"On-treatment viral response to MK-5172\/MK-8742 \u00b1 RBV for 12 weeks in HCV\/HIV-coinfected patients","volume":"22","author":"Sulkowski M","year":"2014","unstructured":"Sulkowski M, Mallolas J, Bourliere M, Gerstoft J, Shibolet O, Nahass R, DeJesus E, Shaughnessy M, Hwang P, Haber B. 2014. On-treatment viral response to MK-5172\/MK-8742 \u00b1 RBV for 12 weeks in HCV\/HIV-coinfected patients, abstr 654LB. Top Antiviral Med 22:324\u2013325. https:\/\/www.iasusa.org\/wp-content\/uploads\/2014\/04\/apr_2014.pdf.","journal-title":"Top Antiviral Med"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30371-9"},{"key":"e_1_3_3_26_2","volume-title":"Norvir (ritonavir) tablet, for oral use, Norvir (ritonavir) oral solution, and Norvir (ritonavir) oral powder [prescribing information]","author":"AbbVie","year":"2017","unstructured":"AbbVie. 2017. Norvir (ritonavir) tablet, for oral use, Norvir (ritonavir) oral solution, and Norvir (ritonavir) oral powder [prescribing information]. AbbVie, Inc., North Chicago, IL. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209512lbl.pdf."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100038"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.142"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)60805-3"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.006"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22655"},{"key":"e_1_3_3_32_2","volume-title":"Tybost [prescribing information]","author":"Gilead Sciences","year":"2017","unstructured":"Gilead Sciences. 2017. Tybost [prescribing information]. Gilead Sciences Inc., Foster City, CA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203094s008lbl.pdf."},{"key":"e_1_3_3_33_2","first-page":"24","article-title":"A clinically meaningful drug-drug interaction observed between Zepatier (grazoprevir\/elbasvir) and Stribild HIV fixed-dose combination in healthy subjects","volume":"6","author":"Feng HP","year":"2016","unstructured":"Feng HP, Caro L, Guo Z, Wolford D, Iwamoto M, Yeh W, Dunnington K, Marricco N, Sterling L, Mirzac A, Moore T. 2016. A clinically meaningful drug-drug interaction observed between Zepatier (grazoprevir\/elbasvir) and Stribild HIV fixed-dose combination in healthy subjects. Rev Antiviral Ther Infect Dis 6:24. http:\/\/regist2.virology-education.com\/Abstractbook\/2016_6.pdf.","journal-title":"Rev Antiviral Ther Infect Dis"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky465"},{"key":"e_1_3_3_35_2","volume-title":"Mavyret [prescribing information]","author":"AbbVie","year":"2017","unstructured":"AbbVie. 2017. Mavyret [prescribing information]. AbbVie Inc., North Chicago, IL. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209394s003lbl.pdf."},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1359254"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12873"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1213"},{"key":"e_1_3_3_39_2","volume-title":"Vosevi [prescribing information]","author":"Gilead Sciences","year":"2017","unstructured":"Gilead Sciences. 2017. Vosevi [prescribing information]. Gilead Sciences, Foster City, CA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209195s000lbl.pdf."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02142-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02142-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:39:25Z","timestamp":1645479565000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02142-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1128\/AAC.02142-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.02142-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"2018-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02142-18"}}